Mirco Pistelli

1.4k total citations
58 papers, 841 citations indexed

About

Mirco Pistelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mirco Pistelli has authored 58 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Mirco Pistelli's work include Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mirco Pistelli is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mirco Pistelli collaborates with scholars based in Italy, United States and France. Mirco Pistelli's co-authors include Rossana Berardi, Stefano Cascinu, Z. Ballatore, Matteo Santoni, M. De Lisa, Miriam Caramanti, Mario Scartozzi, Elena Maccaroni, Alessandro Bittoni and Nicola Battelli and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mirco Pistelli

55 papers receiving 822 citations

Peers

Countries citing papers authored by Mirco Pistelli

Since Specialization

Citations

This map shows the geographic impact of Mirco Pistelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirco Pistelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirco Pistelli more than expected).

Fields of papers citing papers by Mirco Pistelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirco Pistelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirco Pistelli. The network helps show where Mirco Pistelli may publish in the future.

Co-authorship network of co-authors of Mirco Pistelli

This figure shows the co-authorship network connecting the top 25 collaborators of Mirco Pistelli. A scholar is included among the top collaborators of Mirco Pistelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirco Pistelli. Mirco Pistelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 2023 ·European Journal of Cancer ·Carmine Valenza, Dario Trapani, Sara Gandini, (unknown), Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, (unknown), Laura Cortesi, Luca Moscetti, Mirco Pistelli, Rossana Berardi, Alberto Zambelli, Matteo Lambertini, Lucia Del Mastro, Valentina Guarneri, Claudio Vernieri, Giuseppe Curigliano	9
2	First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Camilla Di Nunzio, Elena Collovà, (unknown), Patrizia Vici, Vittorio Gebbia, Maria Rosaria Valerio, Fable Zustovich, (unknown), (unknown), Mirco Pistelli, Francesco Giotta, Valter Torri, Marina Elena Cazzaniga	0
3	1609P COVID-19 outbreak repercussions on breast cancer diagnoses and access to treatment: Preliminary data from the COVID-DELAY study 2021 ·Annals of Oncology ·Rossana Berardi, Giulia Mentrasti, (unknown), Nicla La Verde, Rita Chiari, Maria Silvia Cona, Linda Nicolardi, Cosimo de Filippis, Silvia Oldani, Federica Pecci, (unknown), Marco Rocchi, Agnese Savini, Luca Cantini, Mirco Pistelli	1
4	A Mixed-apprOach program To help women wIth breast cancer stay actiVE (MOTIVE program): A pilot-controlled study 2021 ·Heliyon ·Valentina Natalucci, Francesco Lucertini, Luciana Vallorani, Giorgio Brandi, (unknown), Mirco Pistelli, Rossana Berardi, Maria Gabriella Ceravolo, Elena Barbieri, Marianna Capecci	2
5	Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 2020 ·Supportive Care in Cancer ·Riccardo Giampieri, (unknown), (unknown), (unknown), (unknown), (unknown), Mirco Pistelli, (unknown), Sonila Alia, (unknown), Arianna Vignini, Marina Taus, Rossana Berardi	1
6	Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 2019 ·Clinical Breast Cancer ·Luca Cantini, Mirco Pistelli, Filippo Merloni, Andrea Fontana, Ilaria Bertolini, Claudia De Angelis, (unknown), (unknown), Alfredo Santinelli, Agnese Savini, Elena Maccaroni, (unknown), Alfredo Falcone, Rossana Berardi	10
7	Aromatase Inhibitors in Premenopausal Women with Breast Cancer: The State of the Art and Future Prospects 2018 ·Current Oncology ·Mirco Pistelli, (unknown), Z. Ballatore, Rossana Berardi	46
8	Prognostic impact of CA15-3 pre-treatment levels in ovarian cancer patients 2017 ·Annals of Oncology ·Elena Maccaroni, Riccardo Giampieri, Michela Del Prete, (unknown), R. Bracci, (unknown), (unknown), Francesca Bianchi, Laura Belvederesi, (unknown), (unknown), Mirco Pistelli, Agnese Savini, (unknown), Z. Ballatore, Federica Bini, (unknown), Luca Cantini, (unknown), Rossana Berardi	1
9	BRCA mutations and IGF-R1 expression in modulating sensitivity to Trastuzumab in patients with HER2-positive breast cancer 2016 ·Annals of Oncology ·Mirco Pistelli, Alfredo Santinelli, Matteo Santoni, Francesco Piva, Francesca Bianchi, Tommasina Biscotti, Laura Belvederesi, Z. Ballatore, Giulia Occhipinti, M. De Lisa, (unknown), Nicola Battelli, R. Bracci, Elena Maccaroni, (unknown), Luca Cantini, Rossana Berardi, Stefano Cascinu	1
10	Triple-negative breast cancer and BRCA mutation: looking at the future 2016 ·Annals of Oncology ·Z. Ballatore, Mirco Pistelli, R. Bracci, Francesca Bianchi, Elena Maccaroni, Laura Belvederesi, (unknown), (unknown), M. De Lisa, (unknown), Luca Cantini, (unknown), (unknown), Nicola Battelli, Rossana Berardi	0
11	Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma 2016 ·Supportive Care in Cancer ·Federico Guerra, (unknown), (unknown), (unknown), Marco Bruno Morelli, (unknown), Nicola Battelli, Mirco Pistelli, Rossana Berardi, Stefano Cascinu, (unknown)	25
12	Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer patients: a single Centre experience 2016 ·Annals of Oncology ·Elena Maccaroni, R. Bracci, Riccardo Giampieri, Francesca Bianchi, Laura Belvederesi, (unknown), (unknown), (unknown), (unknown), Mirco Pistelli, (unknown), Nicola Battelli, Z. Ballatore, M. De Lisa, Rossana Berardi	1
13	Endocrine therapy is not effective in BRCA2 mutated breast cancers even when they express hormonal receptors 2015 ·Annals of Oncology ·Mirco Pistelli, Z. Ballatore, R. Bracci, Francesca Bianchi, Elena Maccaroni, Laura Belvederesi, Federica Bini, M. De Lisa, (unknown), (unknown), Nicola Battelli, Alfredo Santinelli, Tommasina Biscotti, Stefano Cascinu	1
14	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials 2015 ·Critical Reviews in Oncology/Hematology ·Matteo Santoni, Alessandro Conti, Kalliopi Andrikou, Alessandro Bittoni, Andrea Lanese, Mirco Pistelli, Francesco Pantano, Bruno Vincenzi, Grazia Armento, Francesco Massari, Giuseppe Tonini, Stefano Cascinu, Daniele Santini	13
15	Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. 2013 ·PubMed ·Mirco Pistelli, (unknown), Nicola Battelli, Alfredo Santinelli, Tommasina Biscotti, Z. Ballatore, Rossana Berardi, Stefano Cascinu	27
16	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach 2013 ·PLoS ONE ·Alessandro Bittoni, Mario Scartozzi, Riccardo Giampieri, Luca Faloppi, Maristella Bianconi, Alessandra Mandolesi, Michela Del Prete, Mirco Pistelli, Luca Cecchini, Italo Bearzi, Stefano Cascinu	56
17	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer 2013 ·OncoTargets and Therapy ·Rossana Berardi, Matteo Santoni, Francesca Morgese, (unknown), (unknown), (unknown), (unknown), Mirco Pistelli, Riccardo Pierantoni, (unknown), (unknown), (unknown), (unknown), Stefano Cascinu	20
18	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients 2012 ·PLoS ONE ·Mario Scartozzi, Cristian Loretelli, Gennaro Galizia, Alessandra Mandolesi, Mirco Pistelli, Alessandro Bittoni, Riccardo Giampieri, Luca Faloppi, Maristella Bianconi, Michela Del Prete, Francesca Bianchi, Laura Belvederesi, Italo Bearzi, Stefano Cascinu	17
19	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients 2011 ·Digestive and Liver Disease ·Mario Scartozzi, Cristian Loretelli, Rossana Berardi, Chiara Pierantoni, Rosa Rita Silva, Davide Mari, Riccardo Giampieri, Luca Faloppi, Mirco Pistelli, Elena Maccaroni, Alessandro Bittoni, Michela Del Prete, Gennaro Galizia, Stefano Cascinu	3
20	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives 2009 ·Cancer Treatment Reviews ·Mario Scartozzi, Alessandro Bittoni, Mirco Pistelli, Gennaro Galizia, Rossana Berardi, Riccardo Giampieri, Luca Faloppi, Stefano Cascinu	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact